Oral Cancer Research Initiative

Oral cancer is one of the most pernicious epithelial malignancies in the world, whose incidence is on the rise. Despite progress in diagnosis and treatment of oral cancer, the 5-year survival rates over the past twenty years have remained at about 50%. Oral cancer disproportionately affects underserved minorities in the US and in the developing countries.

The Oral Cancer Research Initiative (OCRI) is a focused multidisciplinary collaborative that brings together basic scientists, clinicians, public health researchers, engineers, chemists and computational biologists to work on diverse issues related to oral cancer.

Our mission: to elucidate the mechanisms of oral cancer development and progression and to expedite translation of research findings toward diagnosis, prevention, treatment and cure of oral cancer. Our multidisciplinary effort will align research on oral cancer with societal needs. For more information regarding the Oral Cancer Research Initiative please contact ocri@bu.edu

Internal Advisory Board

Rhoda M. Alani, M.D.
Herbert Mescon Professor & Chair, Department of Dermatology, School of Medicine

David M. Center, M.D.
Chief, Pulmonary, Allergy & Critical Care Medicine
Gordon & Ruth Snider Professor of Pulmonary Medicine
Professor of Medicine & Biochemistry
Associate Provost for Translational Research
Director, Boston University Medical Campus Translational Research Institute

David L. Coleman, M.D.
Wade Professor & Chair, Department of Medicine

Ronald B. Corley, Ph.D.
Professor & Chair of Microbiology
Associate Provost for Research, Boston University Medical Campus

Jeffrey W. Hutter, D.M.D., M.Ed.
Dean, Henry M. Goldman School of Dental Medicine
Spencer N. Frankl Professor in Dental Medicine

Katya Ravid, D.Sc., Ph.D.
Professor of Medicine & Biochemistry
Director, Evans Center for Interdisciplinary Biomedical Research

M. Selim Ünlü, M.S.E.E., Ph.D.
Professor of Electrical and Computer Engineering
Associate Director, Boston University Center for Nanoscience and Nanobiotechnology

Roberta F. White, Ph.D.
Associate Dean for Research
Professor of Environmental Health, School of Public Health

External Advisory Board

Thomas J. Glynn, Ph.D.
Director, Cancer Science & Trends
Director, International Cancer Control, American Cancer Society

Jennifer Grandis, M.D.
Director, Head & Neck SPORE
Professor of Otolaryngology, University of Pittsburgh

Bruce Johnson, M.D.
Chief Clinical Research Officer, Dana-Farber Cancer Institute
Professor of Medicine, Harvard Medical School

Scott M. Lippman, M.D.
Director, Head & Neck SPORE
Chair, Thoracic/Head & Neck Medical Oncology
University of Texas MD Anderson Cancer Center

Poul Erik Petersen, D.D.S., D.O.Sc., M.Sc.
Chief, Oral Health Programme, World Health Organization

Marshall Posner, M.D.
Director, Head & Neck Medical Oncology
Director, Office of Cancer Clinical Trials
The Tisch Cancer Institute
Mount Sinai School of Medicine

Jatin P. Shah, M.D., F.A.C.S.
Chairman of the Council of the International Academy of Oral Oncology
Professor of Surgery, Cornell University
Chief of Head & Neck Surgery Service,
Memorial Sloan-Kettering Cancer Center

Dong M. Shin, M.D., F.A.C.P.
Director, Head & Neck SPORE
Professor of Hematology, Oncology & Otolaryngology
Director, Clinical & Translational Cancer Prevention Program
Winship Cancer Institute
Emory University School of Medicine

Gregory T. Wolf, M.D.
Director, Head & Neck SPORE
Professor of Otolaryngology, University of Michigan


OCRI News

  • OCRI Investigators Present at IADR/AADR Annual Meeting in Boston

    May 28, 2015

    The Boston University Henry M. Goldman School of Dental Medicine (GSDM) Oral Cancer Research Initiative (OCRI) had a strong presence at the 93rd General Session & Exhibition of the International Association for Dental Research (IADR) and the 44th annual Meeting & Exhibition of the American Association for Dental Research (AADR), [ More ]

  • Dr. Philip Trackman Receives Funding from Australian Pharmaceutical Company

    May 28, 2015

    The Trackman Laboratory has received funding from Pharmaxis, an Australia-based pharmaceutical company specializing in respiratory and immune diseases, to evaluate the ability of an inhibitor of lysyl oxidase like-2 (LOXL2) activity to inhibit oral cancer growth in mice. Professor and Director of Graduate Programs in the Department of Molecular &... [ More ]

  • Researcher Spotlight: Maria Trojanowska, PhD

    May 28, 2015

    OCRI member, Dr. Maria Trojanowska, is a Professor of Medicine and Director of the Arthritis Center at Boston University School of Medicine. Dr. Trojanowska and her team investigate the molecular and cellular mechanisms regulating extracellular matrix (ECM) synthesis in healthy tissues and in pathological conditions. Their main area of research... [ More ]

News Archive


Also See…